Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-001466
Filing Date
2025-02-14
Accepted
2025-02-14 13:49:10
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9391
2 d11600166_ex99-a.htm EX-99 8061
3 d11600166_ex99-b.htm EX-99 728
  Complete submission text file 0000919574-25-001466.txt   20054
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Subject) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-45385 | Film No.: 25626379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 500 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 500 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 212-848-0519
SAMLYN CAPITAL, LLC (Filed by) CIK: 0001421097 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SCHEDULE 13G